Regeneron and Bayer's Eylea has been racking up sales that have consistently topped analyst expectations since its U.S. rollout in late 2011. Now, new data may help it potentially top them in a market Novartis and Roche got to first.
DKSH, a well-heeled pharma marketing operation, has reupped with Roche, expanding a long-standing agreement to include more of Asia.
Welcome to the hall of shame, where blockbuster drug projections go to die. This list includes some drugs that clearly should never have wound up in Phase III to begin with, a few that were steered back to the clinic in a doomed attempt to mine something positive, and a couple of notable exceptions that may have helped advance the field by exploring the outer limits of new drug technology.
As fervor surrounding a new class of cancer drugs builds, drug giants Merck and Roche are set to roll out new data for their opposing immunotherapy drugs for breast cancer by the end of the year.
There's nothing like same-day FDA approvals to trigger a market showdown--and that's the case for a pair of new idiopathic pulmonary fibrosis (IPF) treatments. After snagging nods from the agency Wednesday, Roche's Esbriet and Boehringer Ingelhem's Ofev will be going head-to-head.
Roche can thank its newly augmented breast cancer portfolio for powering third-quarter sales upward, far enough to surpass analyst estimates. And given the latest data on one of those drugs--Perjeta--more growth could be at hand.
Germany's Wilex has long been on the way out of biotech, but a new collaboration with Roche provides the company with some cash up front and a shot at down-the-line royalties.
Swiss citizens may have recently voted for some of the world's tightest controls on executive pay. But did that keep the Roche and Novartis pharma chiefs from pocketing more than 13 million Swiss francs ($13.6 million) last year? Not according to a new study.
A team from the Singapore-based Agency for Science, Technology and Research has found that a component of green tea has the potential to act as a nano-sized drug delivery vehicle to encapsulate proteins used to fight cancer.
Counterfeiters managed to get fakes of some of Roche's ($RHHBY) top-selling cancer drugs, including Herceptin and MabThera/Rituxan, into the European market this summer. This, among other issues, has motivated Roche's Genentech to have specialty distributors handle these recently conterfeited drugs, as well as Avastin. This decision has outraged some hospitals.